8-K: Inovio Completes BLA for INO-3107, Reports Q3 2025 Results

Inovio Pharmaceuticals announced the completion of its Biologics License Application submission for INO-3107 and reported its third-quarter 2025 financial results, including a significant increase in net loss.

Summary

• Completed the rolling submission of the Biologics License Application (BLA) for lead candidate INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) in adults, requesting priority review.
• Expect to receive BLA file acceptance by year-end 2025, with a potential PDUFA date in mid-2026 if priority review is granted.
• Commercial preparations are continuing for a potential launch of INO-3107 in mid-2026, which would be Inovio's first commercial product and the first DNA medicine in the U.S. if approved.
• Clinical data for INO-3107 showed 81% (26/32) of patients experienced a reduction of one or more surgeries at Year 1 post-treatment, improving to 91% (21/23) by Year 2.
• A 78% reduction in mean annual surgeries was observed at Year 2 compared to the 1-year pre-treatment period (0.9 vs 4.1).
• Results from a Phase 1 proof-of-concept trial evaluating Inovio's next-generation DNA-Encoded Monoclonal Antibody (DMAb™) technology for COVID-19 were published in Nature Medicine.
• Research and Development (R&D) expenses decreased to $13.3 million for Q3 2025 from $18.7 million for Q3 2024.
• General and Administrative (G&A) expenses decreased to $7.9 million for Q3 2025 from $8.6 million for Q3 2024.
• Total operating expenses decreased to $21.2 million for Q3 2025 from $27.3 million for Q3 2024.
• Net loss increased to $45.5 million, or $0.87 per basic and diluted share, for Q3 2025, compared to a net loss of $25.2 million, or $0.89 per basic and diluted share, for Q3 2024.
• The increase in net loss was primarily driven by a $22.5 million non-cash loss on fair value adjustment related to warrant liabilities.
• Cash, cash equivalents, and short-term investments were $50.8 million as of September 30, 2025, down from $94.1 million as of December 31, 2024.
• Current cash, cash equivalents, and short-term investments are estimated to support operations into the second quarter of 2026, with an estimated operational net cash burn of approximately $22 million for Q4 2025.

Sentiment

Score: 4

Explanation: While significant clinical and regulatory progress for INO-3107 and promising next-generation technology developments are positive, the substantial increase in net loss driven by warrant liabilities and the rapidly declining cash position with a short runway into Q2 2026 present considerable financial concerns. The implied need for future capital raises adds to the uncertainty.

Positives

• Completed the rolling Biologics License Application (BLA) submission for INO-3107, requesting priority review, a significant regulatory milestone.
• Strong clinical efficacy data for INO-3107, demonstrating an 81% reduction in surgeries at Year 1 and 91% at Year 2 post-treatment for RRP patients, with a 78% reduction in mean annual surgeries.
• Publication of positive Phase 1 proof-of-concept trial results for next-generation DNA-Encoded Monoclonal Antibody (DMAb™) technology in Nature Medicine, highlighting its potential as a long-acting, scalable, and tolerable alternative to traditional monoclonal antibodies.
• Decreased Research and Development (R&D) expenses to $13.3 million in Q3 2025 from $18.7 million in Q3 2024, reflecting financial discipline.
• Decreased General and Administrative (G&A) expenses to $7.9 million in Q3 2025 from $8.6 million in Q3 2024.
• Overall reduction in total operating expenses to $21.2 million in Q3 2025 from $27.3 million in Q3 2024.
• Preparing for an upcoming presentation of promising preclinical data from the DNA-encoded protein technology (DPROT) program.

Negatives

• Net loss significantly increased to $45.5 million in Q3 2025 from $25.2 million in Q3 2024.
• The primary driver for the increased net loss was a substantial $22.5 million non-cash loss on fair value adjustment related to warrant liabilities.
• Cash, cash equivalents, and short-term investments decreased to $50.8 million as of September 30, 2025, from $94.1 million as of December 31, 2024, indicating a significant reduction in liquidity.
• Current cash balances are projected to support operations only into the second quarter of 2026, suggesting a limited cash runway.
• An estimated operational net cash burn of approximately $22 million for the fourth quarter of 2025.

Risks

• Uncertainties inherent in pre-clinical studies, clinical trials, product development programs, and commercialization activities and outcomes.
• The availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology or develop viable DNA medicines.
• Ability to support the pipeline of DNA medicine products.
• The ability of collaborators to attain development and commercial milestones for licensed products and product sales that will enable future payments and royalties.
• The adequacy of capital resources.
• The availability or potential availability of alternative therapies or treatments for the conditions targeted, including alternatives that may be more efficacious or cost-effective.
• Issues involving product liability.
• Issues involving patents and whether they or licenses to them will provide meaningful protection from others using the covered technologies, or if such proprietary rights are enforceable, defensible, infringe on rights of others, or can withstand claims of invalidity.
• The ability to finance or devote other significant resources necessary to prosecute, protect, or defend proprietary rights.
• The level of corporate expenditures.
• Assessments of technology by potential corporate or other partners or collaborators.
• Capital market conditions.
• The impact of government healthcare proposals and other factors.
• No assurance that any product candidate in the pipeline will be successfully developed, manufactured, or commercialized.
• No assurance that the results of clinical trials will be supportive of regulatory approvals required to market products.
• No assurance that any of the forward-looking information provided will be proven accurate.

Future Outlook

Inovio anticipates receiving FDA file acceptance for its INO-3107 BLA by year-end 2025, with a potential PDUFA date in mid-2026 if priority review is granted. Commercial preparations are advancing for a potential launch of INO-3107 in mid-2026. The company plans to initiate a confirmatory trial for INO-3107, with patient enrollment expected during the BLA review period. Inovio also expects to present promising preclinical data from its DPROT program at the World Federation of Hemophilia Global Forum. Current cash resources are projected to sustain operations into the second quarter of 2026, with an estimated operational net cash burn of approximately $22 million for Q4 2025.

Management Comments

• "I'm very pleased to report that we've completed the rolling submission of our BLA for lead candidate INO-3107. We believe every patient deserves a treatment that reduces exposure to surgery and INO-3107 has the potential to meet that significant need in the RRP community." Dr. Jacqueline Shea, President and CEO.
• "The majority of patients in our Phase 1/2 trial needed fewer surgeries after treatment and showed continued improvement through Year 2 without additional doses, and without surgical interventions during the treatment window to maintain minimal residual disease as required by other treatment modalities." Dr. Jacqueline Shea.
• "As INOVIO works toward a potential approval for INO-3107 in mid-2026, we're also working to advance our next generation DNA medicine candidates." Dr. Jacqueline Shea.
• "Landmark proof-of-concept data on our DMAb technology was recently published in Nature Medicine and we are preparing for an upcoming presentation of promising pre-clinical data from our DNA-encoded protein technology (DPROT) at the World Federation of Hemophilia Global Forum." Dr. Jacqueline Shea.

Industry Context

Inovio's progress with its DNA medicines platform, particularly the BLA submission for INO-3107, positions it as a potential innovator in the treatment of HPV-related diseases like RRP. The potential approval of INO-3107 as the first DNA medicine in the U.S. could validate the broader DNA medicine approach and open new therapeutic avenues. The publication of DMAb technology data in Nature Medicine further highlights Inovio's contribution to next-generation therapeutic protein production, offering a potentially long-acting and scalable alternative to traditional monoclonal antibodies, which could be a significant development in the biotechnology sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison to industry standards or global benchmarks. The focus is on Inovio's internal clinical trial outcomes and regulatory progress for INO-3107 and its proprietary DNA medicine platform.

Stakeholder Impact

• Shareholders face potential for significant value creation if INO-3107 is approved and successfully commercialized, but also dilution risk from potential future capital raises due to the limited cash runway and current financial losses.
• Patients suffering from Recurrent Respiratory Papillomatosis (RRP) could gain access to a novel DNA medicine (INO-3107) that has demonstrated a significant reduction in the need for surgical procedures.
• Employees will continue to focus on advancing the INO-3107 program towards commercialization and developing next-generation DNA medicines, with the company emphasizing financial discipline.
• Regulatory authorities, specifically the FDA, will be reviewing the BLA submission for INO-3107, which could set a precedent for DNA medicines in the U.S.

Next Steps

• Receive FDA file acceptance for the INO-3107 BLA by year-end 2025.
• Await potential PDUFA date for INO-3107 in mid-2026 if priority review is granted.
• Continue commercial preparations for a potential launch of INO-3107 in mid-2026.
• Begin enrolling patients in a confirmatory trial for INO-3107 during the BLA review period.
• Present promising preclinical data from the DPROT program at the World Federation of Hemophilia Global Forum.

Key Dates

Recommendation

The completion of the BLA submission for INO-3107 and the positive clinical data represent a significant de-risking event and a major step towards commercialization, which is a strong positive. However, the substantial increase in net loss, primarily due to a non-cash warrant liability adjustment, and the rapidly dwindling cash reserves with a short runway into Q2 2026, introduce considerable financial risk. While operational expense reductions are positive, the overall financial health necessitates a cautious approach. Investors should hold, awaiting further clarity on the BLA approval, commercialization strategy, and, critically, a clear plan for strengthening the balance sheet and extending the cash runway. The implied need for future capital raises could lead to dilution.

Keywords

Inovio Pharmaceuticals, INO-3107, Recurrent Respiratory Papillomatosis, RRP, DNA medicine, Biologics License Application, BLA, FDA accelerated approval, priority review, DMAb technology, DNA-Encoded Monoclonal Antibody, DPROT, Q3 2025 financial results, biotechnology, HPV-related diseases, cancer, infectious diseases, CELLECTRA